RenovoRx Inc

Company Profile

RenovoRx Inc had its IPO on 2021-08-26 under the ticker symbol RNXT.

The company operates in the Healthcare sector and Biotechnology industry. RenovoRx Inc has a staff strength of 10 employees.

Stock update

Shares of RenovoRx Inc opened at $1.6 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $1.54 - $1.65, and closed at $1.59.

This is a +3.92% increase from the previous day's closing price.

A total volume of 13,700 shares were traded at the close of the day’s session.

In the last one week, shares of RenovoRx Inc have slipped by -5.92%.

RenovoRx Inc's Key Ratios

RenovoRx Inc has a market cap of $18.07 million, indicating a price to book ratio of 2.1661 and a price to sales ratio of 0.

In the last 12-months RenovoRx Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-10964000. The EBITDA ratio measures RenovoRx Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, RenovoRx Inc’s operating margin was 0% while its return on assets stood at -78.08% with a return of equity of -174.67%.

In Q2, RenovoRx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

RenovoRx Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-1.05 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into RenovoRx Inc’s profitability.

RenovoRx Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.0634. Its price to sales ratio in the trailing 12-months stood at 0.

RenovoRx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$6.31 million

Total Liabilities

$1.70 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

RenovoRx Inc ended 2024 with $6.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $6.31 million while shareholder equity stood at $1.19 million.

RenovoRx Inc ended 2024 with $0 in deferred long-term liabilities, $1.70 million in other current liabilities, 1000.00 in common stock, $-36757000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $5.95 million and cash and short-term investments were $5.95 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

RenovoRx Inc’s total current assets stands at $6.31 million while long-term investments were $0 and short-term investments were $0.00. Its net receivables were $0 compared to accounts payable of $872000.00 and inventory worth $0.

In 2024, RenovoRx Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, RenovoRx Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$1.59

52-Week High

$5.745

52-Week Low

$1.45

Analyst Target Price

$11.5

RenovoRx Inc stock is currently trading at $1.59 per share. It touched a 52-week high of $5.745 and a 52-week low of $5.745. Analysts tracking the stock have a 12-month average target price of $11.5.

Its 50-day moving average was $1.9 and 200-day moving average was $2.57 The short ratio stood at 1.44 indicating a short percent outstanding of 0%.

Around 1788.9% of the company’s stock are held by insiders while 2149.5% are held by institutions.